

# Matthias Holdhoff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3968688/publications.pdf>

Version: 2024-02-01

89  
papers

12,689  
citations

136950

32  
h-index

62596

80  
g-index

92  
all docs

92  
docs citations

92  
times ranked

22787  
citing authors

#	ARTICLE	IF	CITATIONS
1	A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vda006.	0.7	14
2	Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2022, 8, 688-700.	1.8	8
3	Approach to the low-grade glioma patient. , 2021, , 136-152.		0
4	IDH $\mu$ mutant brainstem gliomas in adolescent and young adult patients: Report of three cases and review of the literature. <i>Brain Pathology</i> , 2021, 31, e12959.	4.1	7
5	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. <i>Clinical Epigenetics</i> , 2021, 13, 104.	4.1	10
6	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
7	Report of Canonical <i>BCR</i> - <i>ABL1</i> Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 1348-1353.	3.0	3
8	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. <i>Clinical Chemistry</i> , 2021, 67, 1524-1533.	3.2	1
9	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	1.2	4
10	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.7	13
11	Validation of the Coronary Artery Calcium Data and Reporting System (CAC-DRS): Dual importance of CAC score and CAC distribution from the Coronary Artery Calcium (CAC) consortium. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 12-17.	1.3	28
12	Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2020, 7, 52-58.	1.6	1
13	&lt;p&gt;Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8323-8335.	2.0	14
14	Ivosidenib in Isocitrate Dehydrogenase 1 $\mu$ Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	1.6	167
15	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. <i>Case Reports in Oncology</i> , 2020, 13, 508-514.	0.7	15
16	Cerebellar Melanoneurons: An Overlooked and Potentially Important Cell Population. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 242-243.	1.7	0
17	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
18	Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	7
20	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.	1.8	2
21	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
22	Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1571-1578.	4.9	31
23	NIMG-55. A QUANTITATIVE ANALYSIS OF BRAIN VOLUME DYNAMICS IN PCNSL PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE-BASED THERAPY. <i>Neuro-Oncology</i> , 2020, 22, ii160-ii160.	1.2	0
24	<i>Pneumocystis jirovecii</i> prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists. <i>Neuro-Oncology Practice</i> , 2019, 6, 321-326.	1.6	4
25	Discovery of predictive biomarkers in malignant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1089-1090.	1.2	1
26	White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab. <i>Journal of Neuro-Oncology</i> , 2019, 145, 461-466.	2.9	8
27	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
28	Evolving Treatments for Primary Central Nervous System Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 454-466.	3.8	35
29	Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. <i>World Neurosurgery</i> , 2019, 126, e1436-e1448.	1.3	23
30	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. <i>Cancer Investigation</i> , 2019, 37, 67-72.	1.3	4
31	Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 143, 87-93.	2.9	68
32	Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. <i>Diagnostic Pathology</i> , 2019, 14, 16.	2.0	10
33	ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi28.	1.2	0
34	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	5.2	77
35	ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE) Tj ETQq1 1 0.784314 rgsB <i>Neuro-Oncology</i> , 2019, 21, vi23-vi23.	1.2	1
36	The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 347-354.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. <i>Clinical Cancer Research</i> , 2019, 25, 552-561.	7.0	104
38	Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS. <i>Blood</i> , 2019, 134, 2875-2875.	1.4	0
39	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2018, 20, vi15-vi15.	1.2	1
40	PATH-35. FREQUENCY AND CHARACTERISTICS OF H3K27M-MUTATION IN ADULTS WITH RADIOGRAPHICALLY-DETERMINED MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi166-vi166.	1.2	0
41	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 642-645.	4.9	9
42	Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage. <i>Advances in Radiation Oncology</i> , 2018, 3, 582-590.	1.2	20
43	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	27.8	276
44	Glioblastoma in older adults. <i>Aging</i> , 2018, 10, 154-155.	3.1	0
45	Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 3-9.	0.9	17
46	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
47	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 845-852.	1.2	39
48	Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> Hybridization. <i>Clinical Cancer Research</i> , 2017, 23, 3150-3157.	7.0	52
49	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.7	41
50	Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2017, 42, e433-e435.	1.3	49
51	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
52	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
53	Repeatability of <sup>18</sup> F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 393-398.	5.0	27
54	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Actionable Molecular Biomarkers in Primary Brain Tumors. Trends in Cancer, 2016, 2, 338-349.	7.4	41
56	Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1191-1202.	4.9	89
57	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- $\beta$ receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Investigational New Drugs, 2015, 33, 357-370.	2.6	90
58	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9704-9709.	7.1	317
59	Steroid-responsive intracranial germinoma presenting as Holmes <sup>®</sup> tremor: Importance of a tissue diagnosis. Journal of Clinical Neuroscience, 2015, 22, 911-913.	1.5	10
60	First-in-Human Dose Study of the Novel Transforming Growth Factor- $\beta$ Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clinical Cancer Research, 2015, 21, 553-560.	7.0	199
61	Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncology, 2015, 4, 393-398.	3.0	14
62	Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. Journal of Neuro-Oncology, 2015, 124, 307-316.	2.9	36
63	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
64	Evaluation of Eight Plasma Proteins as Candidate Blood-Based Biomarkers for Malignant Gliomas. Cancer Investigation, 2014, 32, 423-429.	1.3	19
65	High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology, 2014, 83, 235-239.	1.1	120
66	Central Nervous System Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1517-1523.	4.9	69
67	Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study. Journal of Medical Cases, 2014, 5, 603-609.	0.7	1
68	Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma. Journal of Neuro-Oncology, 2013, 114, 275-279.	2.9	4
69	“Elderly” patients with newly diagnosed glioblastoma deserve optimal care. Journal of Neuro-Oncology, 2013, 113, 343-344.	2.9	6
70	A 60-Year-Old Indian Male With Altered Sensorium and Extensive Lymphoma of the Scalp. Seminars in Oncology, 2013, 40, e9-e21.	2.2	4
71	Blood-based biomarkers for malignant gliomas. Journal of Neuro-Oncology, 2013, 113, 345-352.	2.9	35
72	Emerging methods for disease monitoring in malignant gliomas. CNS Oncology, 2013, 2, 511-522.	3.0	10

#	ARTICLE	IF	CITATIONS
73	Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1114-1151.	4.9	104
74	Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1165-1173.	4.9	23
75	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. Journal of Neuro-Oncology, 2012, 110, 279-285.	2.9	29
76	Challenges in Supportive Care of Patients with Neoplastic Meningitis. The Journal of Supportive Oncology, 2012, 10, 55-56.	2.3	0
77	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
78	Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. Journal of Neuro-Oncology, 2012, 109, 123-127.	2.9	38
79	Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis. Clinical Cancer Research, 2011, 17, 3551-3557.	7.0	42
80	Controversies in the Adjuvant Therapy of High-Grade Gliomas. Oncologist, 2011, 16, 351-358.	3.7	37
81	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. Oncotarget, 2011, 2, 59-68.	1.8	40
82	Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget, 2011, 2, 739-751.	1.8	151
83	Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. Journal of Neuro-Oncology, 2010, 97, 241-245.	2.9	46
84	Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. Journal of the National Cancer Institute, 2009, 101, 1284-1285.	6.3	79
85	Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. Journal of Neuro-Oncology, 2009, 94, 297-297.	2.9	8
86	Persistent Positron Emission Tomography-Positive Liver Lesions After Successful Chemotherapy in Mediastinal Seminoma. Journal of Clinical Oncology, 2007, 25, 2482-2484.	1.6	1
87	Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells, Molecules, and Diseases, 2005, 34, 181-185.	1.4	67
88	Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome. American Journal of Hematology, 2003, 73, 249-255.	4.1	12
89	Determination of Î±-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571. Blood Cells, Molecules, and Diseases, 2002, 28, 75-85.	1.4	52